FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W1971290010> ?p ?o ?g. }

• W1971290010 endingPage "595" @default.
• W1971290010 startingPage "595" @default.
• W1971290010 abstract "POEMS is an acronym for a rare multisystemic syndrome encompassing polyneuropathy (P), organomegaly (O), endocrinopathy (E), monoclonal gammopathy (M), skin changes (S) and additional features variably expressed [1.Dispenzieri A. Kyle R.A. Lacy M.Q. et al.POEMS syndrome: definitions and long-term outcome.Blood. 2003; 101: 2496-2506Crossref PubMed Scopus (649) Google Scholar]. POEMS syndrome is associated with high vascular endothelial growth factor (VEGF) serum levels. This angiogenic factor likely plays a pathogenic role, in particular for neuropathy, possibly via alteration of endoneurial vessels [2.Scarlato M. Previtali S.C. Carpo M. et al.Polyneuropathy in POEMS syndrome: role of angiogenic factors in the pathogenesis.Brain. 2005; 128: 1911-1920Crossref PubMed Scopus (195) Google Scholar]. Treatment options are still debated, but recently autologous stem-cell transplantation (ASCT) appears to be effective. This approach for POEMS patients, however, was associated with severe morbidity, mainly respiratory failures that appeared to be related to neuromuscular damage [3.Dispenzieri A. Moreno-Aspitia A. Suarez G.A. et al.Peripheral blood stem transplantation in 16 patients with POEMS syndrome, and a review of the literature.Blood. 2004; 104: 3400-3407Crossref PubMed Scopus (173) Google Scholar]. We report a 45-year-old woman presenting with a rapidly progressive sensorimotor polyneuropathy involving all extremities, multiple sclerotic bone lesions, skin hyperpigmentation and hemangiomas, hepatomegaly, peripheral edema and papilledema. A monoclonal immunoglobulin A λ protein was detected (5 g/l) with a bone marrow plasmocytosis (15%). Platelets were 600 × 109/l and cerebrospinal fluid proteins were 30 g/l. Electromyographic and nerve conduction analyses confirmed neuropathy with axonal abnormalities. Within few months appeared walking impossibility, swallowing difficulties and respiratory distress. Serum VEGF was highly elevated at 9700 pg/ml (normal range: 62–707). Steroids treatment was declined by the patient. ASCT was considered at high risk because of her poor condition (Karnofsky score of 50%), neurological defects and respiratory failure. We hypothesized that VEGF inhibition may relieve neuropathy. Bevacizumab therapy was initiated at 10 mg/kg every 2 weeks. Pain relief was observed after two infusions, followed by major improvement in walking and breathing within 10 weeks. This was correlated with a drop in VEGF level (61 pg/ml) and a significant improvement in electromyographic and nerve conduction studies. Treatment was continued for 4 months, and further clinical improvement was observed, confirmed by electroneuromyography and pulmonary function tests. Hepatomegaly and skin abnormalities remained unchanged. Karnofsky score improved at 80%, allowing ASCT conditioned with melphalan (200 mg/m2) to be realized in better conditions. The procedure was well tolerated, and clinical outcome was excellent with a Karnofsky score at 90% 1 year after the procedure. Rapidly evolving neuropathy may hamper to carry out ASCT in POEMS patients. Neurological defects in our POEMS patient has been partially reversed by bevacizumab therapy, further supporting the role of VEGF in this complication. The large biological and clinical heterogeneities of POEMS syndrome could explain variable sensitivities to anti-VEGF therapy [4.Badros A. Porter N. Zimrin A. Bevacizumab therapy for POEMS syndrome.Blood. 2005; 106: 1135Crossref PubMed Scopus (92) Google Scholar, 5.Straume O. Bergheim J. Ernst P. Bevacizumab therapy for POEMS syndrome.Blood. 2006; 107: 4972-4973Crossref PubMed Scopus (82) Google Scholar]. Our report indicates that some patients may benefit from bevacizumab to improve their clinical condition before applying more standard treatments." @default.
• W1971290010 created "2016-06-24" @default.
• W1971290010 creator A5048921562 @default.
• W1971290010 creator A5089255306 @default.
• W1971290010 date "2008-03-01" @default.
• W1971290010 modified "2023-10-12" @default.
• W1971290010 title "Bevacizumab therapy before autologous stem-cell transplantation for POEMS syndrome" @default.
• W1971290010 cites W1981313177 @default.
• W1971290010 cites W2040978620 @default.
• W1971290010 cites W2075068942 @default.
• W1971290010 cites W2159694977 @default.
• W1971290010 cites W2166161087 @default.
• W1971290010 doi "https://doi.org/10.1093/annonc/mdm602" @default.
• W1971290010 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/18209011" @default.
• W1971290010 hasPublicationYear "2008" @default.
• W1971290010 type Work @default.
• W1971290010 sameAs 1971290010 @default.
• W1971290010 citedByCount "51" @default.
• W1971290010 countsByYear W19712900102012 @default.
• W1971290010 countsByYear W19712900102013 @default.
• W1971290010 countsByYear W19712900102014 @default.
• W1971290010 countsByYear W19712900102015 @default.
• W1971290010 countsByYear W19712900102017 @default.
• W1971290010 countsByYear W19712900102018 @default.
• W1971290010 countsByYear W19712900102019 @default.
• W1971290010 countsByYear W19712900102020 @default.
• W1971290010 countsByYear W19712900102021 @default.
• W1971290010 countsByYear W19712900102022 @default.
• W1971290010 countsByYear W19712900102023 @default.
• W1971290010 crossrefType "journal-article" @default.
• W1971290010 hasAuthorship W1971290010A5048921562 @default.
• W1971290010 hasAuthorship W1971290010A5089255306 @default.
• W1971290010 hasBestOaLocation W19712900101 @default.
• W1971290010 hasConcept C126322002 @default.
• W1971290010 hasConcept C141071460 @default.
• W1971290010 hasConcept C142724271 @default.
• W1971290010 hasConcept C16005928 @default.
• W1971290010 hasConcept C2775892965 @default.
• W1971290010 hasConcept C2776210965 @default.
• W1971290010 hasConcept C2776367607 @default.
• W1971290010 hasConcept C2776728111 @default.
• W1971290010 hasConcept C2778551932 @default.
• W1971290010 hasConcept C2909381827 @default.
• W1971290010 hasConcept C2911091166 @default.
• W1971290010 hasConcept C71924100 @default.
• W1971290010 hasConceptScore W1971290010C126322002 @default.
• W1971290010 hasConceptScore W1971290010C141071460 @default.
• W1971290010 hasConceptScore W1971290010C142724271 @default.
• W1971290010 hasConceptScore W1971290010C16005928 @default.
• W1971290010 hasConceptScore W1971290010C2775892965 @default.
• W1971290010 hasConceptScore W1971290010C2776210965 @default.
• W1971290010 hasConceptScore W1971290010C2776367607 @default.
• W1971290010 hasConceptScore W1971290010C2776728111 @default.
• W1971290010 hasConceptScore W1971290010C2778551932 @default.
• W1971290010 hasConceptScore W1971290010C2909381827 @default.
• W1971290010 hasConceptScore W1971290010C2911091166 @default.
• W1971290010 hasConceptScore W1971290010C71924100 @default.
• W1971290010 hasIssue "3" @default.
• W1971290010 hasLocation W19712900101 @default.
• W1971290010 hasLocation W19712900102 @default.
• W1971290010 hasLocation W19712900103 @default.
• W1971290010 hasLocation W19712900104 @default.
• W1971290010 hasOpenAccess W1971290010 @default.
• W1971290010 hasPrimaryLocation W19712900101 @default.
• W1971290010 hasRelatedWork W1500569830 @default.
• W1971290010 hasRelatedWork W1679609229 @default.
• W1971290010 hasRelatedWork W1971290010 @default.
• W1971290010 hasRelatedWork W2092168284 @default.
• W1971290010 hasRelatedWork W2177500853 @default.
• W1971290010 hasRelatedWork W2388167881 @default.
• W1971290010 hasRelatedWork W2396173062 @default.
• W1971290010 hasRelatedWork W2417701358 @default.
• W1971290010 hasRelatedWork W2953802173 @default.
• W1971290010 hasRelatedWork W3159534282 @default.
• W1971290010 hasVolume "19" @default.
• W1971290010 isParatext "false" @default.
• W1971290010 isRetracted "false" @default.
• W1971290010 magId "1971290010" @default.
• W1971290010 workType "article" @default.